Evaluation of different mycobacterial species for drug discovery and
... indicate that new drugs are needed for Tb treatment. While no new anti-Tb agents have been introduced to the market for about three decades, drugs with novel mechanisms of action can amend the current Tb treatment regimen and may provide an effective solution to drug resistance. The main objectives ...
... indicate that new drugs are needed for Tb treatment. While no new anti-Tb agents have been introduced to the market for about three decades, drugs with novel mechanisms of action can amend the current Tb treatment regimen and may provide an effective solution to drug resistance. The main objectives ...
Saurashtra University
... gynecological infections, intra-abdominal infections, and in the treatment of meningococcal meningitis 1, 3 . With some exceptions, agents in the 4-fluoroquinolone classes can also be grouped by their clinical indications. The drugs can be further differentiated based on available formulations, requ ...
... gynecological infections, intra-abdominal infections, and in the treatment of meningococcal meningitis 1, 3 . With some exceptions, agents in the 4-fluoroquinolone classes can also be grouped by their clinical indications. The drugs can be further differentiated based on available formulations, requ ...
Structural elements defining elongation factor Tu mediated
... starting with three G residues to facilitate T7 polymerase recognition. Self-cleavage of the hammerhead ribozyme was completed during one hour of incubation at 608C after five-fold dilution of the transcription mix with 50 mM Tris–HCl pH 8.1 and 20 mM MgCl2 (23). Nucleic acids were recovered by ethan ...
... starting with three G residues to facilitate T7 polymerase recognition. Self-cleavage of the hammerhead ribozyme was completed during one hour of incubation at 608C after five-fold dilution of the transcription mix with 50 mM Tris–HCl pH 8.1 and 20 mM MgCl2 (23). Nucleic acids were recovered by ethan ...
effect of cytochrome p450 2d6 and 3a enzyme inhibition on
... investigated, and the new aspects of its metabolism have been discovered only some years ago (Kalso 2005, Olkkola and Hagelberg 2009). After the introduction of immediate- and extended-release oral oxycodone into the market in the 1990s, the global use of oxycodone has increased rapidly (Coluzzi and ...
... investigated, and the new aspects of its metabolism have been discovered only some years ago (Kalso 2005, Olkkola and Hagelberg 2009). After the introduction of immediate- and extended-release oral oxycodone into the market in the 1990s, the global use of oxycodone has increased rapidly (Coluzzi and ...
Effects of grapefruit juice on the pharmacokinetics of selected
... CYP3A4 substrates observed in these studies makes prediction of the magnitude of interaction for an individual difficult. Concomitant ingestion of grapefruit juice with CYP3A4 substrates with extensive first-pass metabolism and a narrow therapeutic range can increase the risk for adverse effects of ...
... CYP3A4 substrates observed in these studies makes prediction of the magnitude of interaction for an individual difficult. Concomitant ingestion of grapefruit juice with CYP3A4 substrates with extensive first-pass metabolism and a narrow therapeutic range can increase the risk for adverse effects of ...
Gamma-butyrolactone (GBL) - World Health Organization
... however, can be inferred from non-controlled observations. The clinical hallmark of GBL (and 1,4 BD) intoxication in humans is CNS depression with relatively short duration of action, and which is clinically indistinguishable from that of GHB intoxication 29. CNS depression induced by GBL may be acc ...
... however, can be inferred from non-controlled observations. The clinical hallmark of GBL (and 1,4 BD) intoxication in humans is CNS depression with relatively short duration of action, and which is clinically indistinguishable from that of GHB intoxication 29. CNS depression induced by GBL may be acc ...
Determination of Solubility Parameters of Ibuprofen and Ibuprofen
... www.mdpi.com/journal/molecules ...
... www.mdpi.com/journal/molecules ...
PHARMACEUTICAL AND PHARMACOLOGICAL PROFILE OF GUAR GUM AN OVERVIEW Review Article
... volunteers. The bioavailability profile showed that there is a constant and minimum fluctuation in drug delivery was observed [8]. The swelling behaviour and network parameter of guar gum/poly (acrylic acid) semi-interpenetrating poly network hydrogel was studied using free radical polymerization. T ...
... volunteers. The bioavailability profile showed that there is a constant and minimum fluctuation in drug delivery was observed [8]. The swelling behaviour and network parameter of guar gum/poly (acrylic acid) semi-interpenetrating poly network hydrogel was studied using free radical polymerization. T ...
Characterization of Agouti-Related Protein
... agonist to displace labeled antagonist. We have recently demonstrated that an epitope-tagged form of Agouti protein interacts directly with the MC1R in an overlay experiment, but these assays are not quantitative and so do not allow a comparison among different receptors or antagonists (13). Our pre ...
... agonist to displace labeled antagonist. We have recently demonstrated that an epitope-tagged form of Agouti protein interacts directly with the MC1R in an overlay experiment, but these assays are not quantitative and so do not allow a comparison among different receptors or antagonists (13). Our pre ...
Annex 1 - Emcdda
... The "25I" component within 25I-NBOMe refers to the location of the iodine atom on the phenethylamine nucleus. The "NBOMe" component refers to the N-(2-methoxybenzyl) part of the molecule. There are a number of other "NBOMe" derivatives that have been notified to the Early Warning System. These inclu ...
... The "25I" component within 25I-NBOMe refers to the location of the iodine atom on the phenethylamine nucleus. The "NBOMe" component refers to the N-(2-methoxybenzyl) part of the molecule. There are a number of other "NBOMe" derivatives that have been notified to the Early Warning System. These inclu ...
Third Amended Master Consolidated Class Action Complaint
... The Johnson & Johnson Group Has Been the Target of Government Investigations .................................................................................................161 ...
... The Johnson & Johnson Group Has Been the Target of Government Investigations .................................................................................................161 ...
MDMA in humans: factors which affect the neuropsychobiological
... estimating MDMA intake. Many regular users state that it is difficult to remember how many ecstasy tablets they have taken over months and years, and this problem can be exacerbated by variations in MDMA strength and purity (Curran 2000; Schifano, 2000; Cole and Sumnall, 2003; Parrott, 2004); althou ...
... estimating MDMA intake. Many regular users state that it is difficult to remember how many ecstasy tablets they have taken over months and years, and this problem can be exacerbated by variations in MDMA strength and purity (Curran 2000; Schifano, 2000; Cole and Sumnall, 2003; Parrott, 2004); althou ...
drug registration guidance document (drgd)
... normally indicates the number of dilution steps employed (Table 1). As a consequence of different views in various approaches in homeotherapy and because the notion of these terms may depend on the nature of the starting materials, the terms “high potency” and “low potency” cannot be defined unambig ...
... normally indicates the number of dilution steps employed (Table 1). As a consequence of different views in various approaches in homeotherapy and because the notion of these terms may depend on the nature of the starting materials, the terms “high potency” and “low potency” cannot be defined unambig ...
Document
... The lag period before adding other agent(s) should be kept to a minimum to achieve glycemic targets within 6-12 months Unless contraindicated, metformin should be used first line; other agents should be considered in the order they appear in the treatment algorithm Insulin therapy should be initiate ...
... The lag period before adding other agent(s) should be kept to a minimum to achieve glycemic targets within 6-12 months Unless contraindicated, metformin should be used first line; other agents should be considered in the order they appear in the treatment algorithm Insulin therapy should be initiate ...
Full Text
... uncontrolled status epilepticus (Dravet et al., 2005; Ceulemans et al., 2012). Delayed language development, disruption of autonomic function, and motor and cognitive impairment are also associated with this disease. Seizure management includes treatment with benzodiazepines, valproate, and/or stiri ...
... uncontrolled status epilepticus (Dravet et al., 2005; Ceulemans et al., 2012). Delayed language development, disruption of autonomic function, and motor and cognitive impairment are also associated with this disease. Seizure management includes treatment with benzodiazepines, valproate, and/or stiri ...
drug registration guidance document (drgd) - NPRA
... normally indicates the number of dilution steps employed (Table 1). As a consequence of different views in various approaches in homeotherapy and because the notion of these terms may depend on the nature of the starting materials, the terms “high potency” and “low potency” cannot be defined unambig ...
... normally indicates the number of dilution steps employed (Table 1). As a consequence of different views in various approaches in homeotherapy and because the notion of these terms may depend on the nature of the starting materials, the terms “high potency” and “low potency” cannot be defined unambig ...
Chronic tolerance to recreational MDMA
... Given that not every Ecstasy tablet comprises MDMA, how does this affect the use of recreational user data (especially from studies undertaken during the mid-1990s), to debate chronic tolerance to MDMA? The consumption of Ecstasy tablets that do not contain MDMA will generally contribute to the erro ...
... Given that not every Ecstasy tablet comprises MDMA, how does this affect the use of recreational user data (especially from studies undertaken during the mid-1990s), to debate chronic tolerance to MDMA? The consumption of Ecstasy tablets that do not contain MDMA will generally contribute to the erro ...
design synthesis and functionalization of self assembled
... coordination nanocages reported so far are hydrophobic, which greatly limits their applications in aqueous condition. We hypothesize this problem can be circumvented by turning these nanocages into colloids through surface functionalization with hydrophilic polymers and moreover if this supramolecul ...
... coordination nanocages reported so far are hydrophobic, which greatly limits their applications in aqueous condition. We hypothesize this problem can be circumvented by turning these nanocages into colloids through surface functionalization with hydrophilic polymers and moreover if this supramolecul ...
buy iressa in canada
... cereals, green leafy vegetables buy iressa in canada and fruit, and by the time of the other benzodiazepines. Xanax belongs to a potentially fatal dose. Tell your doctor or pharmacist to show you how to recognize the symptoms subside. I have been reported. Here is a diet programme. Endocrine: Impote ...
... cereals, green leafy vegetables buy iressa in canada and fruit, and by the time of the other benzodiazepines. Xanax belongs to a potentially fatal dose. Tell your doctor or pharmacist to show you how to recognize the symptoms subside. I have been reported. Here is a diet programme. Endocrine: Impote ...
human pharmacology of ayahuasca - Multidisciplinary Association
... widely used by the indigenous peoples of northwestern South America. The area of use has been estimated to extend from Panama to Amazonian Peru and Bolivia and from the coastal areas of Colombia and Ecuador to the Río Negro in Brazil (Ott, 1993). While the term ayahuasca, which also designates the p ...
... widely used by the indigenous peoples of northwestern South America. The area of use has been estimated to extend from Panama to Amazonian Peru and Bolivia and from the coastal areas of Colombia and Ecuador to the Río Negro in Brazil (Ott, 1993). While the term ayahuasca, which also designates the p ...
Review: Colchicine, current advances and future prospects
... a toxic natural compound and secondary metabolite commonly produced by plants like Colchicum autumnale and Gloriosa superba. It is originally used to treat rheumatic complaints, especially gout, and still finds its uses for these purposes today despite dosing issues concerning its toxicity. It is al ...
... a toxic natural compound and secondary metabolite commonly produced by plants like Colchicum autumnale and Gloriosa superba. It is originally used to treat rheumatic complaints, especially gout, and still finds its uses for these purposes today despite dosing issues concerning its toxicity. It is al ...
P-Glycoprotein functional activity in peripheral blood lymphocytes. Role of immunosuppressants,
... basolateral membranes, and mediate active transport in absorptive and secretory directions. ...
... basolateral membranes, and mediate active transport in absorptive and secretory directions. ...
Relationship between Type of Endorser and
... had favorable impressions toward Lipitor, and nearly 67% kept taking Lipitor because of Jarvik’s endorsement (“Cholesterol Drugs,” 2008). Could it be that there was a relationship between using Jarvik as an endorser and patients’ favorable attitudes and behaviors toward Lipitor? Would this relations ...
... had favorable impressions toward Lipitor, and nearly 67% kept taking Lipitor because of Jarvik’s endorsement (“Cholesterol Drugs,” 2008). Could it be that there was a relationship between using Jarvik as an endorser and patients’ favorable attitudes and behaviors toward Lipitor? Would this relations ...
coordination of some monodentate and hybrid multident ate
... NMR and IR spectroscopies and mass spectrometry. Some of these complexes have been isolated as single crystals and characterised by X-ray diffraction. The triarylphosphine ligands used in this study were P(4 -CH3 0 C6H4) 3, P(4HOC 6H4)3, P(2 -CH3OC6H4)3, PPh2(2 -CH3OC6H4), P(2 -HOC 6H4)3 and PPh 2(2 ...
... NMR and IR spectroscopies and mass spectrometry. Some of these complexes have been isolated as single crystals and characterised by X-ray diffraction. The triarylphosphine ligands used in this study were P(4 -CH3 0 C6H4) 3, P(4HOC 6H4)3, P(2 -CH3OC6H4)3, PPh2(2 -CH3OC6H4), P(2 -HOC 6H4)3 and PPh 2(2 ...
5 1 Prereview - World Health Organization
... of d-amphetamine available to the blood stream and therefore the CNS(2). Novascreen Biosciences Corporation screened lisdexamfetamine in radioligand-binding studies and found no activity (<50% inhibition at 10μM) for over sixty G-protein or ionchannel receptors, enzymes, or transporters. The pharmac ...
... of d-amphetamine available to the blood stream and therefore the CNS(2). Novascreen Biosciences Corporation screened lisdexamfetamine in radioligand-binding studies and found no activity (<50% inhibition at 10μM) for over sixty G-protein or ionchannel receptors, enzymes, or transporters. The pharmac ...
Drug design
Drug design, sometimes referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. In the most basic sense, drug design involves the design of molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it. Drug design frequently but not necessarily relies on computer modeling techniques. This type of modeling is often referred to as computer-aided drug design. Finally, drug design that relies on the knowledge of the three-dimensional structure of the biomolecular target is known as structure-based drug design. In addition to small molecules, biopharmaceuticals and especially therapeutic antibodies are an increasingly important class of drugs and computational methods for improving the affinity, selectivity, and stability of these protein-based therapeutics have also been developed.The phrase ""drug design"" is to some extent a misnomer. A more accurate term is ligand design (i.e., design of a molecule that will bind tightly to its target). Although design techniques for prediction of binding affinity are reasonably successful, there are many other properties, such as bioavailability, metabolic half-life, side effects, etc., that first must be optimized before a ligand can become a safe and efficacious drug. These other characteristics are often difficult to predict with rational design techniques. Nevertheless, due to high attrition rates, especially during clinical phases of drug development, more attention is being focused early in the drug design process on selecting candidate drugs whose physicochemical properties are predicted to result in fewer complications during development and hence more likely to lead to an approved, marketed drug. Furthermore, in vitro experiments complemented with computation methods are increasingly used in early drug discovery to select compounds with more favorable ADME (absorption, distribution, metabolism, and excretion) and toxicological profiles.